Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity
Abstract Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dr...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-02-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.13250 |
| _version_ | 1811305024586776576 |
|---|---|
| author | Xiaoxiao Guo Hanping Wang Jiaxin Zhou Yue Li Lian Duan Xiaoyan Si Li Zhang Ligang Fang Li Zhang |
| author_facet | Xiaoxiao Guo Hanping Wang Jiaxin Zhou Yue Li Lian Duan Xiaoyan Si Li Zhang Ligang Fang Li Zhang |
| author_sort | Xiaoxiao Guo |
| collection | DOAJ |
| description | Abstract Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dramatically in multiple types of advanced‐stage malignancies. Even though the tolerance and safety profiles are generally good, it has been widely reported that ICIs can cause severe or fatal immune‐related adverse events (irAEs), since the activated T lymphocytes are not specific for tumor cells. Cardiac irAEs appear to occur less frequently than irAEs in other organ systems but are notorious for high mortality. Here, we aim to identify and characterize the ICI‐associated cardiotoxicity and summarize the optional diagnosis and treatment strategies. |
| first_indexed | 2024-04-13T08:18:10Z |
| format | Article |
| id | doaj.art-90b6510191b4430784e404af1adb54d5 |
| institution | Directory Open Access Journal |
| issn | 1759-7706 1759-7714 |
| language | English |
| last_indexed | 2024-04-13T08:18:10Z |
| publishDate | 2020-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj.art-90b6510191b4430784e404af1adb54d52022-12-22T02:54:43ZengWileyThoracic Cancer1759-77061759-77142020-02-0111247548010.1111/1759-7714.13250Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicityXiaoxiao Guo0Hanping Wang1Jiaxin Zhou2Yue Li3Lian Duan4Xiaoyan Si5Li Zhang6Ligang Fang7Li Zhang8Department of Cardiology, Peking Union Medical College Hospital Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Rheumatism and Immunology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Gastroenterology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Endocrinology Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Clinical Laboratory Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Cardiology, Peking Union Medical College Hospital Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaDepartment of Respiratory Medicine Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences Beijing ChinaAbstract Immune checkpoint inhibitors (ICIs) targeting programmed death‐1 (PD‐1), its ligand (PD‐L1), and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA4) have revolutionized cancer treatment by recovering the attack of T lymphocytes on the malignant cells. They have improved clinical outcomes dramatically in multiple types of advanced‐stage malignancies. Even though the tolerance and safety profiles are generally good, it has been widely reported that ICIs can cause severe or fatal immune‐related adverse events (irAEs), since the activated T lymphocytes are not specific for tumor cells. Cardiac irAEs appear to occur less frequently than irAEs in other organ systems but are notorious for high mortality. Here, we aim to identify and characterize the ICI‐associated cardiotoxicity and summarize the optional diagnosis and treatment strategies.https://doi.org/10.1111/1759-7714.13250Cardiotoxicityimmune checkpoint inhibitorsmyocarditis |
| spellingShingle | Xiaoxiao Guo Hanping Wang Jiaxin Zhou Yue Li Lian Duan Xiaoyan Si Li Zhang Ligang Fang Li Zhang Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity Thoracic Cancer Cardiotoxicity immune checkpoint inhibitors myocarditis |
| title | Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity |
| title_full | Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity |
| title_fullStr | Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity |
| title_full_unstemmed | Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity |
| title_short | Clinical manifestation and management of immune checkpoint inhibitor‐associated cardiotoxicity |
| title_sort | clinical manifestation and management of immune checkpoint inhibitor associated cardiotoxicity |
| topic | Cardiotoxicity immune checkpoint inhibitors myocarditis |
| url | https://doi.org/10.1111/1759-7714.13250 |
| work_keys_str_mv | AT xiaoxiaoguo clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT hanpingwang clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT jiaxinzhou clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT yueli clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT lianduan clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT xiaoyansi clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT lizhang clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT ligangfang clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity AT lizhang clinicalmanifestationandmanagementofimmunecheckpointinhibitorassociatedcardiotoxicity |